The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Malozhen S.A.

Krasnov Research Institute of Eye Diseases

Trufanov S.V.

Research Institute of Eye Diseases

Krakhmaleva D.A.

Research Institute of Eye Diseases

Antiangiogenic therapy in the surgical treatment of pterygium

Authors:

Malozhen S.A., Trufanov S.V., Krakhmaleva D.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2020;136(5): 177‑183

DOI: 10.17116/oftalma2020136052177

Read: 1779 times

Download PDF (RU)
Contact the author
Table of contents

ANTIANGIOGENIC THERAPY IN THE SURGICAL TREATMENT OF PTERYGIUM
ANTIANGIOGENIC THERAPY IN THE SURGICAL TREATMENT OF PTERYGIUM

To cite this article:

Malozhen SA, Trufanov SV, Krakhmaleva DA. Antiangiogenic therapy in the surgical treatment of pterygium. Russian Annals of Ophthalmology. 2020;136(5):177‑183. (In Russ.)
https://doi.org/10.17116/oftalma2020136052177

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Analysis the frequency of using Afli­bercept (8 mg) in the treatment of neovascular age-related macu­lar dege­neration and diabetic macu­lar edema compared with other anti-VEGF agents. Russian Annals of Ophthalmology. 2025;(6):92-100
Abstract:

PURPOSE

To evaluate the effectiveness and safety of adjuvant anti-VEGF therapy in the surgical treatment of pterygium, and to determine the indications for its use.

MATERIAL AND METHODS

The study included 67 patients (69 eyes) with grade II—IV pterygium. Patients age was 58.8±12.6 years on average. Best corrected visual acuity (BCVA) varied between 0.01 and 1.0 (0.77±0.24). The patients were divided into 3 groups. The first group included 19 patients (19 eyes) with grade II—III pterygium who underwent «bare sclera» surgery and used aflibercept as adjuvant therapy. The second group included 21 patients (21 eyes) with grade II—IV pterygium who underwent auto conjunctival grafting surgery with no adjuvant therapy. The third group included 27 patients (29 eyes) with grade II—IV pterygium who had it removed in combination with single-time peripheral lamellar keratoplasty (PLK) and underwent adjuvant aflibercept therapy.

RESULTS

Among patients who underwent pterygium excision with adjuvant antiangiogenic therapy there were 5 cases (26%) of relapse during the observation period (23.38±8.96 months), among patients after pterygium excision with auto conjunctival plastic surgery — also 5 cases (24%) of relapse, and among patients who underwent LKP combined with anti-VEGF therapy there was only 1 case (3%) of relapse. Astigmatism has decreased by 0.24±0.5 (p=0.052) in the first group, by 1.21±1.0 (p<0.05) in the second group, and by 1.64±1.54 (p<0.05) in the third group compared with pre-surgical values, thus increasing average BCVA in all 3 patient groups by 0.1±0.13, 0.07±0.11 and 0.15±0.15, respectively.

CONCLUSION

The use of anti-VEGF agents as adjuvant therapy in the surgical treatment of pterygium is a safe method of reducing postoperative inflammation, fibrovascular proliferation and, subsequently, the amount of relapses.

Keywords:

pterygium
aflibercept
anti-VEGF
auto conjunctival plastic surgery
peripheral lamellar keratoplasty

Authors:

Malozhen S.A.

Krasnov Research Institute of Eye Diseases

Trufanov S.V.

Research Institute of Eye Diseases

Krakhmaleva D.A.

Research Institute of Eye Diseases

Received:

25.04.2020

Accepted:

13.06.2020

Close metadata

References:

  1. Tasman W, Jaeger E. Duane’s Clinical Ophthalmology. [Philadelphia]: Lippincott Williams & Wilkins; 2002.
  2. Malozhen SA, Trufanov SV, Krakhmaleva DA. Pterygium: etiology, pathogenesis and treatment. Vestnik oftal’mologii. 2017;133(5):76-83 (In Russ.). https://doi.org/10.17116/oftalma2017133576-83
  3. Tan DT, Liu YP, Sun L. Flow cytometry measurements of DNA content in primary and recurrent pterygia. Invest Ophthalmol Vis Sci. 2000;41:1684-1686.
  4. Talghini S, Shenasi A. Concomitant Examination of Inflammation and Angiogenesis in the Pathogenesis of Primary Moderate Pterygium in a Well-designed Case-control Study. Pakistan Journal of Biological Sciences. 2013; 16(19):1046-1050. https://doi.org/10.3923/pjbs.2013.1046.1050
  5. Coroneo MT, Di Girolamo N, Wakeeld D. The pathogenesis of pterygia. Current Opinion in Ophthalmology. 1999;10:282-288.  https://doi.org/10.1097/00055735-199908000-00011
  6. Di Girolamo N, Chui J, Coroneo M, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Progress in Retinal and Eye Research. 2004;23(2):195-228.  https://doi.org/10.1016/j.preteyeres.2004.02.002
  7. Di Girolamo N, Wakefield D, Coroneo MT. UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci. 2006; 47(6):2430-2437. https://doi.org/10.1167/iovs.05-1130
  8. Barr R, Walker S, Tsang W, et al. Suppressed Alloantigen Presentation, Increased TNF-α, IL-1, IL-1Ra, IL-10, and Modulation of TNF-R in UV-Irradiated Human Skin. Journal of Investigative Dermatology. 1999;112(5):692-698.  https://doi.org/10.1046/j.1523-1747.1999.00570.x
  9. Nishida T, Nakamura M, Mishima H, Otori T. Interleukin 6 promotes epithelial migration by a fibronectin-dependent mechanism. J Cell Physiol. 1992;153(1):1-5.  https://doi.org/10.1002/jcp.1041530102
  10. Strieter RM, Kunkel SL, Elner VM, Martonyi CL, Koch AE, Polverini PJ and Elner SG: Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol. 1992;141:1279-1284. https://doi.org/10.1097/00003226-199010000-00009
  11. Blaudschun R, Sunderkotter C, Brenneisen P, et al. Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo. Br J Dermatol. 2002;146(4):581-587.  https://doi.org/10.1046/j.1365-2133.2002.04669.x
  12. Trufanov SV, Krakhmaleva DA. Pterygium. Etiopathogenetic approach to treatment. Tochka zreniya. Vostok-Zapad. 2018;4:135-138 (In Russ.). https://doi.org/10.25276/2410-1257-2018-4-135-138
  13. Lee D, Cho H, Kim J, Choi J, Joo C. Expression of Vascular Endothelial Growth Factor and Inducible Nitric Oxide Synthase in Pterygia. Cornea. 2001;20(7):738-742.  https://doi.org/10.1097/00003226-200110000-00013
  14. Gumus K, Karakucuk S, Mirza GE, et al. Overexpression of vascular endothelial growth factor receptor 2 in pterygia may have a predictive value for a higher postoperative recurrence rate. Br J Ophthalmol. 2014;98:796-800.  https://doi.org/10.1136/bjophthalmol-2012-301944
  15. Mamikonyan VR, Pivin EA, Krakhmaleva DA. Mechanisms and modern features of corneal neovascularisation suppression. Vestnik oftal’mologii. 2016;132(4):81-87 (In Russ.). https://doi.org/10.17116/oftalma2016132481-87
  16. Egorov EA. Glaukoma: natsional’noe rukovodstvo. M.: GEOTAR-Media; 2014. (In Russ.).
  17. Safianik B. Serious corneoscleral complications after pterygium excision with mitomycin C. British Journal of Ophthalmology. 2002;86(3):357-358.  https://doi.org/10.1136/bjo.86.3.357
  18. Dushku N, John MK, Schultz GS, Reid TW. Pterygia pathogenesis: corneal invasion by matrix metalloproteinase expressing altered limbal epithelial basal cells. Archives of Ophthalmology. 2001;119(5):695.  https://doi.org/10.1001/archopht.119.5.695
  19. Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. Ophthalmology. 2013;120(1):201-208.  https://doi.org/10.1016/j.ophtha.2012.06.066
  20. Sun Y, Zhang B, Jia X, Ling S, Deng J. (2018). Efficacy and Safety of Bevacizumab in the Treatment of Pterygium: An Updated Meta-Analysis of Randomized Controlled Trials. Journal of Ophthalmology. 2018;1-9.  https://doi.org/10.1155/2018/4598173
  21. Wagoner KR, Hettinger ME. Conjunctival autograft transplantation for advanced and recurrent pterygium. Ophthalmology. 1985;92:1461-1470. https://doi.org/10.1016/s0161-6420(85)33831-9
  22. Varssano D, Shalev H, Lazar M, Fischer N. Pterygium excision with conjunctival autograft: true survival rate statistics. Cornea. 2013;32(9):1243-1250. https://doi.org/10.1097/ico.0b013e31828ce09c
  23. Kocamis O, Bilgec M. Evaluation of the recurrence rate for pterygium treated with conjunctival autograft. Graefes Arch Clin Exp Ophthalmol. 2014;252(5): 817-820.  https://doi.org/10.1007/s00417-014-2581-y
  24. Golchin B, Butler T, Robinson L. Long-Term Follow-Up Results of Lamellar Keratoplasty as a Treatment for Recurrent Pterygium and for Scleral Necrosis Induced by Betta-Irradiation. Cornea. 2003;22(7):612-618.  https://doi.org/10.1097/00003226-200310000-00005
  25. Malozhen SA, Trufanov SV, Krakhmaleva DA, Sukhanova EV. Peripheral lamellar keratoplasty in treatment of relapsing pterygium. Vestnik oftal’mologii. 2018;134(5-2):168-173 (In Russ.). https://doi.org/10.17116/oftalma2018134051168
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.